Cetera Advisors LLC Has $6.83 Million Stake in Danaher Co. (NYSE:DHR)

Cetera Advisors LLC grew its holdings in shares of Danaher Co. (NYSE:DHR) by 44.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 27,346 shares of the conglomerate’s stock after acquiring an additional 8,389 shares during the period. Cetera Advisors LLC’s holdings in Danaher were worth $6,829,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Argus Investors Counsel Inc. grew its position in shares of Danaher by 4.2% during the 4th quarter. Argus Investors Counsel Inc. now owns 2,925 shares of the conglomerate’s stock worth $677,000 after buying an additional 119 shares during the period. Trust Point Inc. acquired a new stake in Danaher in the fourth quarter worth $591,000. Walkner Condon Financial Advisors LLC increased its stake in Danaher by 10.0% in the fourth quarter. Walkner Condon Financial Advisors LLC now owns 997 shares of the conglomerate’s stock valued at $231,000 after purchasing an additional 91 shares in the last quarter. Breakwater Capital Group boosted its position in shares of Danaher by 2.5% during the 4th quarter. Breakwater Capital Group now owns 2,229 shares of the conglomerate’s stock worth $517,000 after purchasing an additional 55 shares in the last quarter. Finally, SteelPeak Wealth LLC grew its stake in shares of Danaher by 26.0% in the 4th quarter. SteelPeak Wealth LLC now owns 3,393 shares of the conglomerate’s stock valued at $786,000 after buying an additional 700 shares during the period. 79.05% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently weighed in on DHR shares. Citigroup upped their price target on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Bank of America increased their target price on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Robert W. Baird boosted their price target on shares of Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. SVB Leerink raised their price objective on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Finally, Jefferies Financial Group initiated coverage on shares of Danaher in a research report on Monday, June 3rd. They set a “buy” rating and a $295.00 target price for the company. Six analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Danaher has an average rating of “Moderate Buy” and a consensus target price of $276.88.

Danaher Stock Performance

NYSE:DHR traded down $4.01 during trading on Friday, reaching $276.75. The company’s stock had a trading volume of 3,108,808 shares, compared to its average volume of 3,183,765. The firm has a market cap of $199.87 billion, a price-to-earnings ratio of 46.91, a price-to-earnings-growth ratio of 4.62 and a beta of 0.83. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $281.70. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The firm has a 50 day moving average of $256.29 and a 200-day moving average of $250.77.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same quarter last year, the company posted $2.05 earnings per share. Research analysts expect that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, July 26th. Investors of record on Friday, June 28th were paid a $0.27 dividend. The ex-dividend date of this dividend was Friday, June 28th. This represents a $1.08 annualized dividend and a yield of 0.39%. Danaher’s payout ratio is 18.31%.

Insiders Place Their Bets

In other news, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the transaction, the chief financial officer now owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Linda Filler sold 3,928 shares of Danaher stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $279.50, for a total value of $1,097,876.00. Following the completion of the transaction, the director now directly owns 41,149 shares in the company, valued at approximately $11,501,145.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Matthew Mcgrew sold 16,172 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total value of $4,525,572.48. Following the sale, the chief financial officer now owns 29,407 shares in the company, valued at approximately $8,229,254.88. The disclosure for this sale can be found here. Insiders sold 113,174 shares of company stock valued at $29,775,644 over the last ninety days. 11.10% of the stock is currently owned by insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.